ArtNr |
HY-B0180A-500mg |
Hersteller |
MedChem Express
|
CAS-Nr. |
99011-78-6 |
Menge |
500 mg |
Quantity options |
100 mg
10mM/1mL
200 mg
500 mg
|
Kategorie |
|
Typ |
Inhibitors |
Specific against |
other |
Purity |
99.77 |
Formula |
C14H17ClN4 |
Citations |
bioRxiv. 2024 Apr 20.<br/>Int J Pharm. 2023 Nov 7:648:123583.<br/>J Nanobiotechnology. 2023 Feb 10;21(1):50.<br/>Nat Commun. 2022 Jul 22;13(1):4255.<br/>Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.<br/>protocols.io. 2024 Apr 13.<br/>Virulence. 2023 Dec;14(1):2223394.<br/>ACS Appl Bio Mater. 2019, 2, 874-883.<br/>Am J Respir Cell Mol Biol. 2022 Oct 13.<br/>Biochem Biophys Res Commun. 2024 Feb 15, 149661.<br/>Biomaterials. 2021, 120724.<br/>Biomaterials. 2022 Feb 14;282:121411.<br/>Cell Commun Signal. 2023 Aug 18;21(1):215.<br/>Cell Rep. 2021 Feb 2;34(5):108724.<br/>Diam Relat Mater. 2023 May 26, 110058.<br/>Drug Deliv. 2023 Dec;30(1):2183814.<br/>EMBO Rep. 2022 Feb 3;23(2):e53499.<br/>FEBS Lett. 2021 Aug 13.<br/>J Agric Food Chem. 2024 Jan 3.<br/>J Cell Mol Med. 2024 Apr;28(8):e18356.<br/>J Control Release. 2023 Aug 12;361:443-454.<br/>J Ethnopharmacol. 2024 Jan 2:117711.<br/>J Invest Dermatol. 2021 Oct 20;S0022-202X(21)02369-1.<br/>J Nanobiotechnology. 2022 May 14;20(1):228.<br/>MedComm. 04 March 2022.<br/>Nat Commun. 2016 May 25;7:11724. <br/>Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.<br/>Oxid Med Cell Longev. 12 Oct 2022.<br/>Research Square Preprint. 2021 Oct.<br/>Research Square Preprint. 2023 Nov 17.<br/>Research Square Print. 2023 Feb 1.<br/>Sci Rep. 2024 Mar 4;14(1):5237.<br/>Theranostics. 2023 Apr 9;13(7):2226-2240.<br/>Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.<br/>Pharmacol Res. 2023 Nov 24:198:107016.<br/>[1]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.<br/>[2]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47.<br/>[3]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60.<br/>[4]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46. |
Smiles |
NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C)C.Cl |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
R 837 (hydrochloride) |
Lieferbar |
|
Product Description |
Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2]. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture) |
Shipping |
Room Temperature |
Manufacturers Applications |
COVID-19-anti-virus |
MolecularWeight |
276.76 |
Clinical Information |
Launched |
Manufacturers Research Area |
Cancer; Infection; Inflammation/Immunology |
Solubility |
DMSO : 8 mg/mL (ultrasonic; warming; heat to 50°C)|Ethanol : 3.85 mg/mL (ultrasonic)|H2O : 4.8 mg/mL (ultrasonic)|Methanol : 24 mg/mL (ultrasonic) |
Target |
Autophagy; HSV; SARS-CoV; Toll-like Receptor (TLR) |
Manufacturers Target |
Autophagy; HSV; SARS-CoV; Toll-like Receptor (TLR) |
Isoform |
HSV-1; TLR7 |
Manufacturers Pathway |
Anti-infection; Autophagy; Immunology/Inflammation |
Manufacturers Product type |
Reference compound |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.